Relay Therapeutics, Inc.
RLAY
$7.77
$0.283.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -16.49% | -76.27% | -78.26% | -60.83% | -61.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.49% | -76.27% | -78.26% | -60.83% | -61.22% |
| Cost of Revenue | -17.63% | -16.20% | -5.86% | -3.35% | 2.66% |
| Gross Profit | 17.67% | 9.02% | -2.94% | -1.53% | -8.33% |
| SG&A Expenses | -18.16% | -7.65% | 0.48% | 2.11% | 2.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.74% | -14.55% | -4.63% | -2.29% | 2.69% |
| Operating Income | 17.77% | 8.73% | -2.41% | -1.65% | -7.16% |
| Income Before Tax | 13.79% | 3.49% | -1.30% | 1.25% | -5.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.79% | 3.49% | -1.30% | 1.25% | -5.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.79% | 3.49% | -1.30% | 1.25% | -5.90% |
| EBIT | 17.77% | 8.73% | -2.41% | -1.65% | -7.16% |
| EBITDA | 17.71% | 8.70% | -2.50% | -1.62% | -7.14% |
| EPS Basic | 33.03% | 22.77% | 15.40% | 14.13% | 2.54% |
| Normalized Basic EPS | 36.37% | 26.95% | 14.06% | 12.21% | 2.68% |
| EPS Diluted | 33.03% | 22.77% | 15.40% | 14.13% | 2.54% |
| Normalized Diluted EPS | 36.37% | 26.95% | 14.06% | 12.21% | 2.68% |
| Average Basic Shares Outstanding | 28.67% | 26.91% | 22.04% | 16.58% | 8.73% |
| Average Diluted Shares Outstanding | 28.67% | 26.91% | 22.04% | 16.58% | 8.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |